Article
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
International journal of clinical oncology - 1 Dec 2015
Yokoyama Yuhei, Sonobe Makoto, Yamada Tetsu, Sato Masaaki, Menju Toshi, Aoyama Akihiro, Sato Toshihiko, Chen Fengshi, Omasa Mitsugu, Date Hiroshi
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials. However, the effect of gefitinib treatm...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Adenosquamous
- Carcinoma, Large Cell
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors
- Female
- Gefitinib
- Humans
- Lung Neoplasms